Urinary matrix metalloproteinase activity is not significantly altered in patients with renal cell carcinoma

Urology

Volumn 67, Issue 4, 2006, Pages 848-850

  Cannon Jr , Glenn M ^a,b   Getzenberg, Robert H ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 4; MATRIX METALLOPROTEINASE;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RECURRENCE; COLLAGEN DEGRADATION; CONTROLLED STUDY; DIAGNOSTIC TEST; ENZYME ACTIVITY; FLUORESCENCE ANALYSIS; HUMAN; KIDNEY CARCINOMA; NEPHRECTOMY; PRIORITY JOURNAL; RETROPERITONEUM; STATISTICAL SIGNIFICANCE; URINALYSIS;

AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; MATRIX METALLOPROTEINASES; MIDDLE AGED;

EID: 33646008568     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2005.10.029     Document Type: Article

References (17)

1. American Cancer Society. What Are the Key Statistics for Kidney Cancer (Renal Cell Carcinoma) (2004). http://www.cancer.org Revised 12/21/05. American Cancer Society. Available at http://www.cancer.org.
2. Bazzett L.B., Magnus M., Taylor D.D., et al. Urinary matrix metalloproteinases as a potential screening test for gynecologic malignancies. Gynecol Oncol 90 (2003) 435-442
3. Chan L.W., Moses M.A., Goley E., et al. Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy. a longitudinal study of protein kinetics throughout tumor progression and therapy. J Clin Oncol 22 (2004) 499-506
4. Zhang X., Yamashita M., Uetsuki H., et al. Angiogenesis in renal cell carcinoma. evaluation of microvessel density, vascular endothelial growth factor, and matrix metalloproteinases. Int J Urol 9 (2002) 509-514
5. Sier C.F.M., Casetta G., Verheijen J.H., et al. Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma. a comparison with clinically used tumor markers. Clin Cancer Res 6 (2000) 2333-2340
6. Gerhards S., Jung K., Koenig F., et al. Excretion of matrix metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinoma. Urology 57 (2001) 675-679
7. Moses M.A., Wiederschain D., Loughlin K.R., et al. Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res 58 (1998) 1395-1399
8. Takahashi M., Oka N., Naroda T., et al. Prognostic significance of matrix metalloproteinases-2 activation ratio in renal cell carcinoma. Int J Urol 9 (2002) 531-538
9. Cho N.H., Shim H.S., Rha S.Y., et al. Increased expression of matrix metalloproteinase 9 correlates with poor prognostic variables in renal cell carcinoma. Eur Urol 44 (2003) 560-566
10. Kallakury B.V., Karikehalli S., Haholu A., et al. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res 7 (2001) 3113-3119
11. Sherief M.H., Low S.H., Miura M., et al. Matrix metalloproteinase activity in urine of patients with renal cell carcinoma leads to degradation of extracellular matrix proteins. possible use as a screening assay. J Urol 169 (2003) 1530-1534
12. Mitchell T.L., Pippin J.J., Devers S.M., et al. Incidental detection of preclinical renal tumors with electron beam computed tomography. report of 26 consecutive operated patients. J Comp Assist Tomogr 24 (2000) 843-845
13. Agrez M., Gu X., and Giles W. Matrix metalloproteinase 9 activity in urine of patients at risk for premature delivery. Am J Obstet Gynecol 181 (1999) 387-388
14. Makrakis E., Grigoriou O., Kouskouni E., et al. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in plasma/serum and urine of women during term and threatened preterm labor. a clinical approach. J Matern Fetal Neonatal Med 14 (2003) 170-176
15. De Ceuninck F., Sabatini M., Renoux V., et al. Urinary collagen type II C-telopeptide fragments are sensitive markers of matrix metalloproteinase-dependent cartilage degradation in rat adjuvant-induced arthritis. J Rheum 30 (2003) 1561-1564
16. Chromek M., Tulllus K., Hertting O., et al. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in acute pyelonephritis and renal scarring. Pediatr Res 53 (2003) 698-705
17. Tashiro K., Koyanagi I., Ohara I., et al. Levels of urinary matrix metalloproteinase-9 (MMP-9) and renal injuries in patients with type 2 diabetic nephropathy. J Clin Lab Anal 18 (2004) 206-210